Finance

Lists
Q3 2026 earnings • released • EPS beat +12,40% • Revenue miss -0,73%
See results
PRGO:NYSE
Perrigo Company PLC
15,85 USD
+0,89%
(+0,14) 1D
15,85 USD
0,00% (0,00)
After hours
Closed: 6-ноя., 16:00:04 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PRGO...
Open
15,50 USD
High
15,97 USD
Low
15,25 USD
Mkt. cap
2,20 млд
Avg. vol.
2,59 млн
Volume
2,31 млн
Dividend
7,32%
Quarterly dividend
0,29 USD
Ex-dividend date
2026-ж., 28-авг.
52-wk high
16,80 USD
52-wk low
9,22 USD
EPS
-12,84 USD
Beta
0,70
Shares outstanding
138,80 млн
No. of employees
8 миң
Open
15,50 USD
High
15,97 USD
Low
15,25 USD
Mkt. cap
2,20 млд
Avg. vol.
2,59 млн
Volume
2,31 млн
Dividend
7,32%
Quarterly dividend
0,29 USD
Ex-dividend date
2026-ж., 28-авг.
52-wk high
16,80 USD
52-wk low
9,22 USD
EPS
-12,84 USD
Beta
0,70
Shares outstanding
138,80 млн
No. of employees
8 миң
News stories
From web sources and news partners
Profile
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park. Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value. Wikipedia
About Perrigo Company PLC
CEOMurray S. Kessler
Employees8,1 миң
Founded1887
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 2 analysts giving stock ratings to PRGO in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for PRGO in the last 3 months.
Highest
Current 15,85 USD
19,00 USD (+19,87%)
Average
17,00 USD (+7,26%)
Lowest
15,00 USD (-5,36%)
Analyst
Recommendation
Action
Price target
Projected
Date
Susan Anderson
Canaccord Genuity
Buy
Reiterated
19,00 USD
+19,9%
11/05/2026
Chris Schott
J.P. Morgan
Hold
Maintained
15,00 USD
-5,4%
10/21/2026
Christine Dooley
Argus Research
Hold
Maintained
-
-
05/19/2026
Keith Devas
Jefferies
Hold
Maintained
23,00 USD
+45,1%
10/27/2025
Last report
2026-ж., 4-ноя.
Fiscal period
Q3 2026
0,60 USD / 0,53 USD
+12,40%beat
Revenue / Est. (USD)
988,60 млн / 995,90 млн
-0,73%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
1,11 млд
969,20 млн
1,02 млд
988,60 млн
Cost of goods sold
747,40 млн
643,70 млн
708,90 млн
601,60 млн
Cost of revenue
747,40 млн
643,70 млн
708,90 млн
601,60 млн
Research and development expenses
21,80 млн
24,60 млн
23,70 млн
21,90 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
255,60 млн
267,30 млн
251,20 млн
271,70 млн
Operating expense
249,00 млн
291,90 млн
274,60 млн
293,60 млн
Total operating expenses
996,40 млн
935,60 млн
983,50 млн
895,20 млн
Operating income
113,20 млн
33,60 млн
39,30 млн
93,40 млн
Other non operating income
-10,70 млн
3,70 млн
10,10 млн
-3,30 млн
EBT including unusual items
-1,33 млд
-408,60 млн
105,50 млн
-18,10 млн
EBT excluding unusual items
68,70 млн
-1,30 млн
-8,50 млн
52,20 млн
Income tax expense
82,90 млн
-18,70 млн
16,90 млн
-3,80 млн
Effective tax rate
-6,23%
4,58%
16,02%
20,99%
Other operating expenses
-28,40 млн
-
-300,00 миң
-
Net income
-1,42 млд
-398,60 млн
74,50 млн
-27,50 млн
Net profit margin
-127,80%
-41,13%
7,28%
-2,78%
Earnings per share
0,77
0,43
0,50
0,60
Interest and investment income
-
-
-
-
Interest expense
-52,80 млн
-49,00 млн
-47,00 млн
-37,90 млн
Net interest expenses
-52,80 млн
-49,00 млн
-47,00 млн
-37,90 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
199,10 млн
116,90 млн
116,20 млн
194,10 млн
Gain or loss from assets sale
-
-
-129,50 млн
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору